TradingViewAPR 212 min read$NRXS

Neuraxis Inc Expects Net Sales Of About $1.6 Million For Three Months Ended March 31, 2026

Neuraxis Inc has announced its net sales expectations for the three months ending March 31, 2026. The company anticipates achieving approximately $1.6 million in net sales during this period. This news was reported by Reuters.

Original reporting

TradingView · Refinitiv

Published Apr 21, 2026, 9:49 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Apr 21, 2026, 10:30 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$NRXS

Bullish

medium confidence

Mentioned

$NRXS

alphai data visualization · based on TradingView

Decision brief

The 30-second read

$NRXSBullishMed

Why it matters

The sales forecast indicates potential growth, which may positively influence investor sentiment and stock valuation.

Market read

The news is relevant for investors holding or considering NRXS, especially those with a short-term trading horizon.

What to watch

Broader market conditions and upcoming earnings reports could influence stock movement more significantly than this forecast.

Timing: Immediate (within the next 1-2 weeks)

Background

Neuraxis Inc operates in the biotech/healthcare sector, with a focus on innovative medical solutions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NRXSBullishMedium confidence

Context

The news about Neuraxis Inc's sales forecast has a direct impact on its stock, NRXS.

Expected impact

Moderate upward movement in stock price within the next 1-2 weeks.

Evidence & confidence

Sales forecast suggests positive outlook; however, actual results may vary, and market reaction depends on broader economic factors.

Market effects

Sector

Potential positive sentiment for the biotech/healthcare sector, especially for companies with similar profiles.

Regional

Limited regional impact; primarily affects investors in the company's primary market.

Global

Minimal global market impact; company-specific news.

Counterpoint

What could challenge this read

If actual sales fall short of expectations, the stock could experience a correction or decline.

Key entities

Company
Neuraxis Inc
A biotech company specializing in medical solutions.

Read at source ← All news

AUG 14

$NRXSMed

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis (NRXS) shares fell after Q2 2026 results for the quarter ended June 30. Revenue rose to $1.9M, up 115.7% year over year, and loss per share narrowed to $0.19. Net loss and operating loss widened to $2.1M each. Gross margin increased to 85.9% from 83.6% as average selling price rose 28% to $992. Cash was $8.3M.

tradingview.com6 min

AUG 12

$NRXSMedAI 8/10

NeurAxis (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.

fool.com6 min

AUG 11

$NRXSMed

NeurAxis Posts Record Q2 2026 Results On PENFS Growth

NeurAxis (NRXS) reported Q2 2026 revenue of $1.9M, up 116% from $0.9M in Q2 2025, citing expanded payer coverage after Category I CPT code assignment for PENFS. Gross margin rose 230 bps. Operating cash use improved to $1.0M, with cash of $8.3M at June 30, 2026. The company also cited VA contract access and FDA clearance for IB-Stim.

rttnews.com4 min

AUG 11

$NRXSMedAI 8/10

NeurAxis, Inc.: NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth

NeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.

finanznachrichten.de4 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min